Skip to content

Enterprise value at other companies

Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$16.37B+47.7%
Axsome Therapeutics logo
Axsome TherapeuticsAXSM
$8.56B+52.9%
Biogen logo
BiogenBIIB
$30.08B+34.9%
Alkermes logo
AlkermesALKS
$7.12B+41.2%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$13.41B+18.5%
TG Therapeutics logo
TG TherapeuticsTGTX
$5.62B-11.1%

Other financials

Income statement

See full
Revenue--100%
Operating income-$105.9M-41.7%
Net income-$92.6M-33.6%
EPS (diluted)-$3.20+2.7%

Balance sheet

See full
Cash & equivalents$536.7M+223%
Total debt$1.4M+31.3%
Total equity$1.4B+221%
Total assets$1.5B+205%

Cash flow

See full
Operating cash flow-$86.2M-62.5%
CapEx$62.0K
Free cash flow-$86.2M-62.6%

Valuation

See full
Market cap$7.87B+1,075%

Profitability

See full
Operating margin-3,927.5%-1,497pp
Net margin-3,658.5%-1,388pp
FCF margin-3,067.4%-1,030pp

Returns & leverage

See full
Return on equity-35.3%-10.9pp
Debt / equity0.0×
Current ratio15.9×+7.4×

Where this comes from

Calculated from Praxis Precision Medicines, Inc.’s reported figures.

The official record: Praxis Precision Medicines, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Praxis Precision Medicines, Inc.'s enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Praxis Precision Medicines, Inc.'s enterprise value?
Praxis Precision Medicines, Inc. (PRAX) reported enterprise value of $8.44B in Q1 2026.
How has Praxis Precision Medicines, Inc.'s enterprise value changed year-over-year?
Praxis Precision Medicines, Inc.'s enterprise value increased by 1309.5% year-over-year, from $598.67M to $8.44B.
What is the long-term trend for Praxis Precision Medicines, Inc.'s enterprise value?
Over 5 years (2020 to 2025), Praxis Precision Medicines, Inc.'s enterprise value has grown at a 26.4% compound annual growth rate (CAGR), from $2.17B to $7.01B.
What does enterprise value mean?
What it would cost to buy the entire business, debt included and cash netted out.
How do you interpret enterprise value?
The capital-structure-neutral valuation base — used in EV/EBITDA and EV/Sales to compare companies with different leverage on a like-for-like footing.
How does enterprise value compare across companies?
Comparable across non-financial companies via the EV multiples it feeds; not used for banks and insurers.